SG11201602020QA - Polyethylene glycol-containing composition - Google Patents

Polyethylene glycol-containing composition

Info

Publication number
SG11201602020QA
SG11201602020QA SG11201602020QA SG11201602020QA SG11201602020QA SG 11201602020Q A SG11201602020Q A SG 11201602020QA SG 11201602020Q A SG11201602020Q A SG 11201602020QA SG 11201602020Q A SG11201602020Q A SG 11201602020QA SG 11201602020Q A SG11201602020Q A SG 11201602020QA
Authority
SG
Singapore
Prior art keywords
polyethylene glycol
containing composition
composition
glycol
polyethylene
Prior art date
Application number
SG11201602020QA
Other languages
English (en)
Inventor
Kenji Murai
Kazuhito Yamada
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11201602020QA publication Critical patent/SG11201602020QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
SG11201602020QA 2013-09-20 2014-09-18 Polyethylene glycol-containing composition SG11201602020QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013195329 2013-09-20
PCT/JP2014/074698 WO2015041294A1 (ja) 2013-09-20 2014-09-18 ポリエチレングリコール含有組成物

Publications (1)

Publication Number Publication Date
SG11201602020QA true SG11201602020QA (en) 2016-04-28

Family

ID=52688941

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602020QA SG11201602020QA (en) 2013-09-20 2014-09-18 Polyethylene glycol-containing composition

Country Status (17)

Country Link
US (1) US20160228420A1 (cg-RX-API-DMAC7.html)
EP (1) EP3047850A4 (cg-RX-API-DMAC7.html)
JP (2) JP5856264B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160060656A (cg-RX-API-DMAC7.html)
CN (1) CN105555271A (cg-RX-API-DMAC7.html)
AU (1) AU2014322111A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016006153A2 (cg-RX-API-DMAC7.html)
CA (1) CA2924628A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690621A1 (cg-RX-API-DMAC7.html)
HK (2) HK1221407A1 (cg-RX-API-DMAC7.html)
IL (1) IL244648A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016003566A (cg-RX-API-DMAC7.html)
MY (1) MY163236A (cg-RX-API-DMAC7.html)
PH (1) PH12016500461A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201602020QA (cg-RX-API-DMAC7.html)
TW (1) TW201518291A (cg-RX-API-DMAC7.html)
WO (1) WO2015041294A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3272360B1 (en) 2015-03-17 2022-11-23 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition comprising polypeptide
HK1246641A1 (zh) 2015-03-18 2018-09-14 参天制药株式会社 缓释性医药组合物
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
TWI755356B (zh) * 2015-07-01 2022-02-21 日商參天製藥股份有限公司 含檸檬酸酯之緩釋劑之用途
CN106902117A (zh) * 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 一种预防或治疗脉络膜新生血管形成的药物
JP7018939B2 (ja) * 2016-09-26 2022-02-14 ルヤン (スーチョウ) バイオロジー サイエンス アンド テクノロジー カンパニー,リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833692B (en) * 1982-05-28 1985-02-27 Beecham Group Plc Pharmaceutical formulations
JPS59101478A (ja) * 1982-11-29 1984-06-12 Sunstar Inc リグスチライドを安定に配合した水系組成物
JPH09110698A (ja) * 1995-10-19 1997-04-28 Taiho Yakuhin Kogyo Kk 経口用医薬組成物の製造法
EP1717229B1 (en) * 2004-02-17 2011-06-15 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した4−ピリジルアルキルチオ基を有する新規環式化合物
ES2368153T3 (es) * 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
US20060153920A1 (en) * 2004-09-24 2006-07-13 Ketan Amin Lyophilized pharmaceutical compositions
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
JP2009521493A (ja) 2005-12-23 2009-06-04 アルコン,インコーポレイテッド 眼への受容体チロシンキナーゼ阻害(RTKi)化合物の送達のための医薬製剤
CN101687042A (zh) 2007-07-20 2010-03-31 爱尔康公司 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂
CA2706448C (en) * 2007-11-26 2016-08-16 Merial Limited Solvent systems for pour-on formulations for combating parasites
EP2403342A4 (en) 2009-03-03 2013-06-05 Alcon Res Ltd PHARMACEUTICAL COMPOSITION FOR IL-ADMINISTRATION OF TYROSINE KINASE RECEPTOR INHIBITING COMPOUNDS (RTKI)
MX2012000749A (es) * 2009-07-17 2012-01-27 Santen Pharma Co Ltd Bencensulfonato de 2-[[[2-[(hidroxiacetil) amino]-4-piridinil]meti l] tio]-n-[4-(trifluorometox)fenil]-3-piridincarboxamida, cristal del mismo, cristal polimorfo de este y metodos para la produccion de estos.
LT3158991T (lt) * 2010-01-28 2021-07-12 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos

Also Published As

Publication number Publication date
CN105555271A (zh) 2016-05-04
JP2016094442A (ja) 2016-05-26
BR112016006153A2 (pt) 2017-08-01
JP2015083565A (ja) 2015-04-30
JP5856264B2 (ja) 2016-02-09
EP3047850A1 (en) 2016-07-27
KR20160060656A (ko) 2016-05-30
HK1220632A1 (zh) 2017-05-12
MY163236A (en) 2017-08-30
US20160228420A1 (en) 2016-08-11
CA2924628A1 (en) 2015-03-26
HK1221407A1 (en) 2017-06-02
TW201518291A (zh) 2015-05-16
AU2014322111A1 (en) 2016-04-07
WO2015041294A1 (ja) 2015-03-26
IL244648A0 (en) 2016-04-21
PH12016500461A1 (en) 2016-05-16
EP3047850A4 (en) 2017-05-10
MX2016003566A (es) 2016-06-02
EA201690621A1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
PL3065569T3 (pl) Kompozycja
HUE044039T2 (hu) Biokatalitikus készítmény
EP3020778A4 (en) Adhesive-agent composition
EP3006525A4 (en) ASPHALT-URETHANE COMPOSITION
GB201318489D0 (en) Composition
GB201319540D0 (en) Composition
GB201320919D0 (en) Composition
GB201317388D0 (en) Composition
EP3064513A4 (en) Polyrotaxane-containing composition
GB201320303D0 (en) Composition
GB201319538D0 (en) Composition
GB201306984D0 (en) Composition
GB201317105D0 (en) Novel Composition
EP3033392A4 (en) Mechano-responsive composition
IL244648A0 (en) A preparation containing polyethylene glycol
GB201322772D0 (en) Composition
GB201317196D0 (en) Composition
GB201307622D0 (en) Composition
PL2883925T3 (pl) Kompozycja na bazie polipropylenu
GB201319923D0 (en) Novel composition
GB201420672D0 (en) Composition
GB201308502D0 (en) Composition
GB201310513D0 (en) Novel composition
GB201301774D0 (en) Composition
GB201305439D0 (en) Statin composition